medical glp 1 coverage The evolving landscape of anti-obesity medication in Medicaid Blog | Discover Your Weight

The most common treatment-emergent AEs were gastrointestinal in nature and mostly mild in severity

Visible fat reduction typically appears at 4-8 weeks

However, as key patents begin to expire in the late 2020s, the market is expected to open to generic and biosimilar competition

Key takeaways The free version of MeAgain covers the everyday core of GLP-1 tracking: shot and dose logging with reminders, side effects on a 0-10 scale, food logging by barcode or search, protein and water targets, and a weight trend view

Thus, it is difficult to reach consensus about the indication of MO as an adjuvant therapy in the prevention and treatment of DM and well-designed intervention studies in patients with prediabetes and DM are certainly needed

[DOI] [PMC free article] [PubMed] [Google Scholar] 79.elik Tekeli M, Yaln Y, Verdi H, Akta Y, elebi N